Business UpdateMay 26, 2026, 11:07 AM
Alaunos Reports Broad Metabolic Improvements with ALN1003
AI Summary
Alaunos Therapeutics announced an integrated preclinical readout for ALN1003, its investigational oral candidate for obesity and metabolic disorders. The findings from two non-GLP diet-induced obesity mouse studies showed broad metabolic improvements, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and better liver health. While these early results are positive, the company reported a cash position of approximately $0.354 million as of March 31, 2026, with a cash runway extending only into the second quarter of 2026, indicating a need for additional financing.
Key Highlights
- ALN1003 demonstrated reductions in body weight and fat mass in obese mouse studies.
- ALN1003 improved insulin sensitivity, with lower fasting insulin and HOMA-IR.
- Enhanced adipose function was observed, including higher adiponectin and adiponectin-to-leptin ratio.
- ALN1003 led to improved liver health, with lower liver weight, enzymes, and reduced hepatic steatosis.
- High-dose ALN1003 group showed lower blood glucose (197 vs 320 mg/dL) and total cholesterol (162 vs 209 mg/dL).
- Cash and cash equivalents were approximately $0.354 million as of March 31, 2026.
- Current cash runway extends into the second quarter of 2026, requiring additional financing.
Price Impact
More from TCRT